Bayer AG
https://www.bayer.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bayer AG
AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA
After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.
Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
Lilly’s Early Bird Verzenio Goes After Up To S4bn Worm With Early Breast Cancer Nod
Given the requirement for patients to have a Ki-67 score of at least 20%, the challenge now is to alter physicians’ thinking around Ki-67 testing, execs told Scrip.
Apnimed Moves Closer To Phase III With Sleep Apnea Drug
Apnimed is going to conduct one more Phase II study in sleep apnea, mainly to assess subjective endpoint questionnaires, and then hopes to launch a Phase III program by autumn of 2022.
Company Information
- Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
-
- Actus Therapeutics, Inc.
- AskBio
- Asklepios BioPharmaceutical, Inc.
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics
- BrainVectis
- Algeta ASA
- Bayer CropScience AG
- Bayer Consumer Care AG
- Berlex Laboratories
- BlueRock Therapeutics
- Conceptus Inc.
- Dihon Pharmaceutical Group Co., Ltd.
- Intendis GmbH
- Jenapharm
- Medrad Inc.
- Possis Medical
- Schering AG
- Monsanto Company
- Zeptosens AG
- KaNDy Therapeutics
- Vividion Therapeutics, Inc.